Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US : a cross-sectional study by L. Neri et al.
Neri et al. Health and Quality of Life Outcomes 2012, 10:139
http://www.hqlo.com/content/10/1/139RESEARCH Open AccessCharacterizing the relationship between health
utility and renal function after kidney
transplantation in UK and US: a cross-sectional
study
Luca Neri1,2,6*, Phil McEwan3, Karin Sennfält4 and Kesh Baboolal5Abstract
Background: Chronic allograft nephropathy (CAN) occurs in a large share of transplant recipients and it is the
leading cause of graft loss despite the introduction of new and effective immunosuppressants. The reduction in
renal function secondary to immunologic and non-immunologic CAN leads to several complications, including
anemia and calcium-phosphorus metabolism imbalance and may be associated to worsening Health-Related
Quality of Life. We sought to evaluate the relationship between kidney function and Euro-Qol 5 Dimension Index
(EQ-5Dindex) scores after kidney transplantation and evaluate whether cross-cultural differences exist between UK
and US.
Methods: This study is a secondary analysis of existing data gathered from two cross-sectional studies. We enrolled
233 and 209 subjects aged 18–74 years who received a kidney transplant in US and UK respectively. For the present
analysis we excluded recipients with multiple or multi-organ transplantation, creatinine kinase ≥200 U/L, acute renal
failure, and without creatinine assessments in 3 months pre-enrollment leaving 281 subjects overall. The
questionnaires were administered independently in the two centers. Both packets included the EQ-5Dindex and
socio-demographic items. We augmented the analytical dataset with information abstracted from clinical charts and
administrative records including selected comorbidities and biochemistry test results. We used ordinary least
squares and quantile regression adjusted for socio-demographic and clinical characteristics to assess the association
between EQ-5Dindex and severity of chronic kidney disease (CKD).
Results: CKD severity was negatively associated with EQ-5Dindex in both samples (UK: ρ= −0.20, p=0.02; US: ρ=
−0.21, p=0.02). The mean adjusted disutility associated to CKD stage 5 compared to CKD stage 1–2 was Δ= −0.38
in the UK sample, Δ= −0.11 in the US sample and Δ= −0.22 in the whole sample. The adjusted median disutility
associated to CKD stage 5 compared to CKD stage 1–2 for the whole sample was 0.18 (p<0.01, quantile regression).
Center effect was not statistically significant.
Conclusions: Impaired renal function is associated with reduced health-related quality of life independent of
possible confounders, center-effect and analytic framework.
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Kidney transplantation (KTX) is the treatment of choice
in End Stage Renal Disease. In the EU and the US the
number of transplantations performed increased in the
last 15 years but waiting lists for transplantation continue
to grow because demand exceeds organ supply [1,2]. Graft
survival at 1 year is about 98% and 90% in UK and US
respectively [3,4]. Unfortunately, graft survival beyond five
years has remained unchanged since the 1970s : Chronic
allograft nephropathy (CAN) occurs in a large share of
transplant recipients and it is the leading cause of late allo-
graft loss despite the introduction of new and effective
immunosuppressant [5]. Paradoxically, the widely used
calcineurin inhibitors, though effective for immunosup-
pression, are nephrotoxic, impair glucose homeostasis and
thus contribute to late allograft loss and cardiovascular
mortality [6-9]. Immunosuppressive regimens that pre-
serve renal function may lead to a reduction in graft fail-
ure. Additionally, renal impairment affects several body
functions and cause symptoms that may reduce health-
related quality of life (HRQOL).
We have recently shown that impaired renal function is
associated with reduced health-related quality of life in
North-American kidney transplant recipients [10]. How-
ever residual confounding due to lack of information
concerning clinical history of diabetes and cardiovascular
diseases could not be ruled out as an alternative expla-
nation of our previous findings. Additionally, to our know-
ledge there is no data concerning the possible effect of
cross-cultural differences on the association between kid-
ney function and health utilities among European and
North-American patients. Since cross-cultural differences
in quality of life [11-13] might influence the outcome of
cost-effectiveness analyses, it is important to evaluate
whether the association of health utilities and renal func-
tion is confirmed in the European context. In the present
study we evaluated the relationship between health uti-
lities and kidney function after transplantation in patients
enrolled in UK and US and whether cross-cultural diffe-
rence exists between these two countries.
Methods
Subjects and procedures
Data was obtained from KTX patients enrolled at the kid-
ney transplant facilities of the Renal Unit at the Cardiff
and Wales NHS Trust in Cardiff, UK (n=209) and Saint
Louis University Hospital, St. Louis, MO (n=233);
Description of US sample and data collection procedures
Patients were identified from the renal departmental data-
base of the Saint Louis University Hospital from January
2008 to June 2008. All adult patients (18–74 years old)
with a documented kidney transplantation were asked to
answer a self-administered questionnaire during a regularvisit at the transplant clinic (n=282). Patients providing
informed consent were 233 (82% of the original sample).
We excluded patients with multi-organ or multiple trans-
plant, and those with no serum creatinine measurements
in the 3 months prior to the interview. Since severe acute
health events may affect quality of life and determine tran-
sient variation in Glomerular Filtration Rate (GFR) we also
excluded patients who underwent major surgery in the
months prior to enrollment and those with markers of
acute cellular damage (Creatine-Kinase > 200 U/L). The
final sample resulted in 137 patients. Information inclu-
ding biochemistry assessments results obtained in the 3
months prior to interview and lifetime medical history
was abstracted from clinical charts, transplant coordina-
tors records and electronic medical records. We evaluated
the accuracy of data reporting across the 3 different
sources by evaluating the agreement of laboratory test
results performed on the same date for each subject. Since
the agreement was almost perfect (ρ=0.99 for all labora-
tory test results considered) we merged the information
into one common clinical database in order to maximize
data completeness. The Saint Louis University Institu-
tional Review Board approved the study protocol.
Description of UK sample and data collection procedures
All patients registered in the renal departmental database
of the Cardiff and Vale NHS Trust in September 2002
(n=1251) were asked to answer a self-administered ques-
tionnaire. Of them 157 were on Continuous Ambulatory
Peritonale Dialysis, 268 were on hemodialysis, 115 were
on CKD pre-dialysis stage, and 711 received a transplan-
tation. All patients treated at the renal clinic received a
postal-survey at their home while those on chronic dialysis
at the time of survey were asked to complete the question-
naire during a regular dialysis session . . Patients providing
the informed consent were 33.3% of the original sample
(29,4% among transplant recipients). For the present ana-
lysis we included all adult patients with a documented kid-
ney transplant who completed the survey questionnaire
(n=209 of whom 14 were on dialysis after graft failure at
the time of survey). and had at least one serum creatinine
measurement in the 3 months prior to the interview
(n=144). No patient with markers of acute cellular damage
in the 3 months prior to survey return date were identified
(Creatine-Kinase > 200 U/L). Clinical data including
serum creatinine concentrations and medical history were
abstracted from the clinical database of the Cardiff and
Vale NHS Trust.
Outcome
Our outcome measure was the Euro-QOL 5-Dimension
Index (EQ-5Dindex). Its classification system consists of 5
attributes (Mobility, Self-Care, Usual Activities, Pain/Dis-
comfort, and Anxiety/Depression) defining unique 5-digit
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to 33333 for the worst possible state of health [14]. Since
data from this study may be of particular relevance for
cost-effectiveness analyses, we used the tariffs estimated
by Shaw et al. to calculate the EQ-5Dindex score for the US
sample [15] and the tariffs developed by Dolan [16] for the
UK sample, which allow extensive comparability.
Predictor and covariates
We obtained clinical information from patients’ charts. We
collected all laboratory test results recorded in the 3 month
period prior to the date of questionnaire administration
(serum creatinine, albumin, hemoglobin, Alanine Trans-
aminase (ALT), Aspartate Transaminase (AST), creatine
kinase, glucose, phosphorus and calcium). We estimated
Glomerular Filtration Rate (GFR) with the MDRD equa-
tion (4-variable) [17]. We classified patients according
to renal function with the National Kidney Foundation
Chronic Kidney Disease (CKD) staging system [17] (CKD
1–2, eGFR ≥ 60 ml/min/1.73 m2; CKD 3, 60 ml/min/
1.73 m2 > eGFR ≥ 30 ml/min/1.73 m2; CKD 4, 30 ml/
min/1.73 m2 > eGFR ≥ 15 ml/min/1.73 m2; CKD 5, eGFR
< 15 ml/min/1.73m2 or patient on dialysis). Both ques-
tionnaire administered in US and UK included a section
on socio-demographic characteristics (age, gender, educa-
tion, ethnicity, employment status). For the US sample,
depression was defined by self-reported medical diagnosis
in the 12 months prior to the interview or prescription of
antidrepssant/anti-anxiety medication as reported in clin-
ical charts. For the UK sample the same comorbidity were
defined using ICD9 codes listed in Quan H. et al. [18], and
Li, B., et al. [19]. Lifetime diagnoses of diabetes and car-
diovascular diseases were abstracted from clinical charts
(electronic records and hardcopies) in both samples. Dia-
betes was defined by ICD-9 (or ICD-10) codes (compli-
cated and uncomplicated as defined in Quan H. et al.
[18]) anytime, prescription of insulin or any anti-diabetic
drug in the 90 days screening period. Cardio-vascular dis-
ease was defined by ICD-9 (or ICD-10) codes anytime in
patient’s history (myocardial infarction, congestive heart
failure, peripheral vascular diseases and cerebrovascular
diseases (Quan H. et al. [18]).
Analysis
Descriptive statistics were calculated and reported as
mean ± standard deviation (or median with interquartile
range) for continuous variables and frequency for categor-
ical variables. Differences in socio-demographic and clin-
ical characteristics across CKD stages were tested by χ2
for categorical variables and Analysis of Variance (or
Kruskall-Wallis test when appropriate) for continuous
variables. We evaluated the unadjusted associations
between CKD severity, glucose, AST, hemoglobin, phos-
phorus, calcium, and Albumin serum concentrations withSpearman’s correlation coefficient. Spearman's correlation
was also used to test unadjusted associations between
eGFR (or CKD stages) and quality of life.
Ordinary Least Square (OLS) models are traditionally
adopted to analyze quality of life data. Under ideal condi-
tions they have attractive properties: the conditional mean
is an easy-to-interpret, parsimonious representation of the
relationship between a continuous outcome and a pre-
dictor variable. Additionally, economic models used in
cost-effectiveness analysis adopt adjusted means from
OLS models in Quality-Adjusted Life Years (QALY) calcu-
lation. For this reason we initially used general linear
models to obtain adjusted association estimates. Since
EQ-5Dindex scores were strongly skewed and OLS regres-
sion assumptions were not satisfied, we identified the




 QOL⋅100ð Þ þ 1002
p
:1;
where QO^L is the transformed dependent variable of the
general linear model and QOL is the raw health utility
score.
We specified 2 consecutive steps for the GLM ana-
lyses. In the first step we included renal function
alone to assess the unadjusted coefficients of association.
Variables included in the second step were age, gender,
ethnicity, months since transplant, diagnosis of diabetes,
hypertension, cardiovascular diseases, anxiety/depression,
ALT, AST, glucose levels and center of enrollment. From
the second step, we obtained adjusted means for each
CKD category (as defined above). Results were back-
transformed into the original scale, correcting for back-
transformation bias [20]. Significance of trend across CKD
categories was assessed by partial Spearman’s correlation
including all variables entered at each consecutive step.
Since the distribution of the EQ-5Dindex score was
strongly skewed and a relevant ceiling effect was observed,
we used Quantile Regression to evaluate the consistency
of the association between renal impairment and HRQOL
at the 15th, 30th, 50th, 70th and 85th quantile of the out-
come distribution [21] Quantile regression minimizes
mean absolute distance at a given quantile, rather than
modeling the conditional mean as in standard regression.
Quantile regression is robust to departures from ordinary
least square assumptions. In quantile regression, a quan-
tile, such as the median, depends on the ranks of the Y
values, and not on specific values in the tails of the distri-
bution. Quantile regression was introduced by Koenker
and Bassett (1978) [22], for the analysis of linear and non-
linear response models. Useful features of quantile regres-
sion include (a) the models can be used to characterize
the entire conditional distribution of a dependent variable;
(b) the resulting estimated coefficients from quantile
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dependent variable and violation of normality and homo-
scedasticity of the error term; (c) the resulting estimators
are more efficient than those from OLS in the case that
the error term is non-normal; (d) potentially different
solutions at different quantiles may be interpreted as dif-
ferences in the response of the dependent variable to
change in the regressors at various points in the condi-
tional distribution of the dependent variable; e) parameter
estimates can be interpreted as change in the dependent
variable per unit change in the independent variable,
allowing direct comparison with OLS parameter estimates.
We modeled the relationship of CKD stages (categorical
variable) with HRQOL and calculated adjusted medians
using parameters estimates obtained with Quantile Regres-
sion. We modeled the relationship between eGFR with
HRQOL using the raw outcome data. Models have been
adjusted for age, gender, education, ethnicity, time since
transplant, diagnosis of diabetes, hypertension, cardiovas-
cular diseases, glucose levels and AST. In all models (OLS
and Quantile Regression) renal function was included
alternatively as a continuous (eGFR) or categorical variable.
Center effect was accommodated by including in the
regression models an indicator variable denoting the cen-
ter of enrollment and its interaction term with the main
predictor of the analysis. Parameter estimates in all analysis
on the continuous predictor refer to a 10 ml/min./1.73 m2
change in eGFR.
Blood concentrations of Hemoglobin, Albumin, Cal-
cium and Phosphorus were not considered as confoun-
ders in the statistical models since they may be part of
the causal pathway linking CKD severity and HRQOL.
In order to evaluate whether the association between
eGFR and HRQOL was partially independent from the
hypothesized mediators we included those variables to
the statistical models in a secondary analysis.
We considered P values < 0.05 as statistically significant
and p<0.10 as marginally significant. We used SAS 9.2W
to conduct all the analyses.
Power considerations
For the main outcome (mean EQ-5D index utility esti-
mate), the pooled sample size would achieve ~80% power
of detecting a small effect size of 0.23 in a ANOVA test of
4 groups of similar size. This effect size corresponds to a
0.04 difference across CKD classes, a difference considered
clinically significant [16,23-25].
Results
Demographic and clinical characteristics of study sample
are summarized in Table 1. The majority of subjects had
mild or moderate CKD (stage 1-2-3, 62.3% and 74.3% in
UK and US respectively, p<0.01). The mean eGFR was
39.8 (STD= 22.2) in the UK sample and 53.3 (28.0) in theUS sample. UK patients were more likely to have hyper-
tension and had a transplant for a longer time while
had higher hemoglobin and calcium levels and were
less likely to have diabetes and depression (Table 1).
Patients with more advanced CKD had lower hemoglobin
(ρ = −0.40; p<0.001), albumin (ρ = −0.35; p<0.001), and
calcium (ρ = −0.25; p<0.001) serum concentration while
phosphorus levels were directly correlated with the seve-
rity of renal disease (ρ = 0.45; p<0.001).
The median EQ-5Dindex scores in the two samples
were 0.73 (UK, IQ range = 0.23) and 0.83 (US, IQ range =
0.20). CKD severity was associated to EQ-5Dindex score in
both samples (UK: ρ= −0.20, p=0.02; US: ρ= 0.21, p=0.02).
The mean unadjusted disutility associated to CKD
stage 5 compared to CKD stage 1–2 was Δ= −0.22
(p<0.01) in the pooled sample, Δ= −0.25 in the UK sample
(p=0.01) and Δ= −0.09 (p=0.04) in the US sample (p
values based on 1-way ANOVA, pre-specified linear
contrast).
The trend in EQ-5Dindex across CKD stages evaluated
with Spearman’s partial correlation was ρ= −0.18 (p<0.01;
pooled sample) , ρ= −0.20 (p<0.01; UK sample) , ρ= −0.18
(p<0.01; US sample) after adjustment for age, gender, cen-
ter of enrollment, diabetes, cardiovascular diseases, an-
xiety or depression, hypertension, ALT, AST, months since
transplant. The mean adjusted disutility associated to
CKD stage 5 compared to CKD stage 1–2 was Δ= −0.38
in the UK sample and Δ= −0.11 in the US sample (Figure 1
and Table 2). After removing the 14 patients on dialysis,
only 3 patients remained in CKD stage 5 and the associ-
ation between CKD severity and HRQOL in the UK sam-
ple was not statistically significant (not shown). No
significant interaction between age, gender, and eGFR was
observed. After including mean serum hemoglobin, albu-
min and phosphorus in the regression models the associ-
ation between CKD severity and EQ-5Dindex was strongly
attenuated and lost statistical significance. The interaction
term between center of enrollment and CKD severity was
not significant in any model.
Since the interaction between CKD severity and center
of enrollment was not significant, we tested the associ-
ation between renal impairment and EQ-5Dindex with
quantile regression in the pooled sample. Results from
quantile regression are summarized in Figures 1 and 2.
The adjusted median disutility associated to CKD stage
5 compared to CKD stage 1–2 for the whole sample was
0.18 (Wald test for trend across categories, p<0.01),
slightly smaller than the adjusted mean disutility estimated
from GLM (0.22, Wald test for trend across categories,
p<0.01) (Figure 1). According to the results obtained
evaluating the quantile process (τ being evaluated: 0.15,
0.30, 0.50, 0.70, 0.85) the association between eGFR
(entered as a continuous variable) and EQ-5Dindex was
slightly stronger in the upper tail of the outcome
Table 1 Socio-demographic and clinical characteristics of study sample
Characteristics UK Sample (N=144) US sample (N=137)
Mean (STD) or N (%) p*
CKD stage <0.01
CKD stage 1-2 24 (16.8) 51 (37.5)
CKD stage 3 65 (45.5) 50 (36.8)
CKD stage 4 37 (25.9) 26 ( 19.1)
CKD stage 5 17 * (11.9) 9 (6.6)
Women 56 (39.2) 46 (33.3) 0.35
Age 52.0 (13.8) 49.1 (12.9) 0.07
Months since Transplant 63.7 (40.9) 39.5 (52.8) <0.01
Diabetes 26 (18.2) 46 (33.3) <0.01
Cardiovascular Disease (CVD) 44 (30.1) 31 (22.6) 0.13
Hypertension (HTN) 82 (57.3) 40 (29.2) <0.01
Depression/Anxiety 5 (3.5) 15 (11.0) 0.01
Albumin 4.1 (0.3) 4.0 (0.4) 0.02
Hemoglobin 12.9 (1.6) 12.0 (2.0) <0.01
Calcium 9.8 (0.5) 9.2 (0.9) <0.01
Phosphorus 3.3 (1.1) 3.1 (0.8) 0.08
Characteristics of study samples. * Fourteen subjects were returned to dialysis at the time of survey. * p values based on Χ2 or Student’s t-test.
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(τ=0.15) to 0.06 (τ=0.85) and were not significant at
τ<0.30 (Figure 2a). In the upper half of the outcome distri-
bution (τ>0.50) the relationship between eGFR and EQ-
5Dindex was non-linear: the coefficient estimate for eGFR
2
ranged from −0.003 to −0.004 and was statistically signifi-
cant at the 5% confidence level (Figure 2b). The inter-
action term between the indicator variable denoting the
center of enrollment and eGFR was not significant at any
percentile of the outcome variable.
Discussion
According with previous findings [10,26], we observed a
statistically significant association between kidney dis-
ease severity and health utilities. This relationship wasFigure 1 Health Related Quality of Life across CKD stages in
the whole sample.robust to adjustment for several confounders and was
observed in both the US and UK samples. However after
including hemoglobin, phosphorus and albumin serum
concentrations in the analysis, the association of CKD
severity and EQ-5D index was strongly attenuated and
was not statistically significant. Since Chronic Kidney
Disease is associated with reduced hematopoiesis, accu-
mulation of waste products, mineral metabolism imbal-
ance and chronic inflammation, our results suggest that
that the association between HRQOL and CKD could
mostly be explained by its related functional impair-
ments. However, hypotheses concerning meditational
effects are beyond the scope of our cross-sectional de-
sign and should be further tested in longitudinal studies
adopting appropriate statistical techniques (i.e. path ana-
lysis or structural equation modeling).
We have found no evidence of a moderating center ef-
fect on the relationship between HRQOL and CKD se-
verity in both OLS and Quantile regression framework.
However the difference across centers in the estimated
disutility associated to CKD stage 5 compared to CKD
stage 1–2 was large and clinically significant according
to proposed thresholds defining minimal clinically im-
portant difference [16,23-25] and merits further investi-
gation. Previous research have highlighted possible
cross-cultural discrepancies in health-related quality of
life [11-13]. However, US preference-based algorithm
produces scores with a smaller range than the UK
scores, possibly resulting in smaller difference scores
and partially contributing to cross-national differences
Table 2 Adjusted mean HRQOL scores in study sample
CKD stage 1–2 (eGFR ≥60) CKD stage 3 (60 > eGFR ≥ 30) CKD stage 4 (30 > eGFR ≥ 15) CKD stage 5 (eGFR<15)
Sample Mean EQ-5D index P-value
US 0.83 0.85 0.78 0.72 0.04
UK 0.64 0.58 0.49 0.28 0.02
Adjusted mean EQ-5Dindex scores by kidney function classes. Means estimated with general linear models. Confidence levels refer to partial Spearman’s correlation
coefficient. All models have been adjusted for age, gender, months since transplant, diagnosis of diabetes, hypertension, cardiovascular diseases, anxiety/
depression and center of enrollment. The interaction term between center and CKD classes was not statistically significant.
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patients in the US sample had a functioning graft, the
CKD stage 5 group in UK sample included 14 patients
who returned to dialysis after graft loss at the moment
of the interview. After removing from the analysis all
patients on dialysis after graft failure only 3 patients
remained in CKD stage 5 group (UK sample), preventing
a statistically stable estimation of association. Whether
patients with failed graft should be included in the ana-
lysis of health utility after kidney transplant is debatable.
Returning to dialysis is the necessary course of events
for CKD stage 5 patients if survival is to be significantly
prolonged and this choice is part of the natural history
of the disease for all patients with severe renal impair-
ment. While it is conceivable that graft failure mayFigure 2 Relationship between estimated Glomerular Filtration
Rate and Health Related Quality of Life.impact on patients’ physical and emotional status beyond
the effects of glomerular filtration loss, dialysis partially
substitutes for bodily functions otherwise insufficient in
CKD 5 patients on conservative treatment. Which effect
is predominant in transplant patients is a matter of em-
pirical testing. Ideally the HRQOL reported by CKD stage
5 patients on conservative treatment should be contrasted
against that of those returned on dialysis. However such a
design is particularly challenging since transplant patients
on stage 5 spend little time on conservative therapy and
are often treated in different locations when they return
to dialysis. In the only study indirectly allowing such a
comparison there was no apparent differences in general
HRQOL and health utility scores between dialysis
patients and CKD stage 5 on conservative treatment [26].
However the sample size of these subgroups was very
small and replications of such studies would be of great
importance.
It is worth noticing that the difference observed across
CKD classes is clinically significant in both samples
[16,23-25]: the unadjusted and adjusted differences across
CKD classes in our sample were equal or larger than the
suggested threshold for the minimal clinically important
difference in health utility measures. The observed disutil-
ity associated with severe CKD corresponded to 40 and
138 days of healthy life lost for every year in CKD stage 5
compared to CKD stage 1–2 in the US and UK sample
respectively.
Finally, we used quantile regression to evaluate the
consistency of the association between renal impairment
and HRQOL at the 15th, 30th, 50th, 70th and 85th quan-
tile of the outcome distribution and to corroborate results
from OLS regression. Even though statistically significant,
median regression, which is equivalent to a quantile re-
gression estimated for τ=0.50, yielded somewhat smaller
disutility estimates compared to general linear models
(ordinary least square). The quantile process estimated
entering eGFR as a continuous variable indicate that the
relationship between eGFR and HRQOL was slightly
stronger in the upper tail of the outcome distribution.
The difference in CKD-related disutility between the 15th
and the 85th percentile of the outcome distribution
exceeds the suggested threshold for clinical significance
in utility scores, thus indicating that patients with other-
wise better conditions suffer a bigger utility penalty form
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health conditions. As a consequence our results suggest
that unobserved factors might moderate the association
of renal function and HRQOL. Several factors has been
shown to moderate the relationship between health status
and QOL including income [27], social support [28], per-
sonality traits [29] and contextual factors [30]. In our
sample neither gender nor age moderated the relationship
between quality of life and renal function. However our
study was not designed to test moderating effects by mea-
sured clinical characters and other potentially important
factors on the observed relationship.
The strengths of the present study are: i) our data
expands the current knowledge on cross-national HRQOL
studies; ii) we adjusted for several known correlates of
HRQOL in multivariable regression ; iii) we used multiple
serum creatinine assessments collected in the 3 month
period prior to enrollment to define study groups in order
to minimize classification bias; iv) we confirmed the
consistency of our results under different analytic frame-
works. However, our study presents some limitations.
First, we lacked information on possibly important con-
founders such as type of transplant (i.e. living/deceased
donor), immunosuppression regimen, patients’ personality
traits. As a consequence residual confounding cannot be
ruled out as an alternative explanation of our results. One
additional limitation of this study is its correlational
design. Additionally data collection was differently per-
formed in the US and UK studies, which may partially bias
our cross-national comparison. Further, only a small frac-
tion of UK eligible patients responded to the questionnaire
leaving a potential for selection bias possibly limiting the
generalizability of our results: our sample had poorer renal
function and were more likely to have hypertension and
diabetes compared to the general KTX population in UK
[31,32]. Finally, cross-sectional studies cannot provide evi-
dence of causality: even though our results are consistent
with the hypothesis that the severity of renal disease and
CKD-related functional impairments negatively affects
patients’ wellbeing, reverse causality cannot be ruled out
with our data.
Conclusions
In the present cross-national cross-sectional study, we
observed that a decline in kidney function was asso-
ciated with worsening health utility estimates following
kidney transplantation. This association was robust for
adjustment for several established correlates of HRQOL
and was confirmed in both UK & US centers. Even
though the center effect was not statistically significant,
the magnitude of the difference in health disutilities
observed in the two centers merits further evaluation.
Results from quantile regression confirmed the validity
of the association between eGFR and EQ-5Dindex scoresobserved under OLS analytic framework and suggests
that unobserved factors might moderate this association.
Further studies specifically designed to characterize such
moderating factors might help identify patients more
likely to benefit from kidney function preserving strat-
egies. The present analysis provides further evidence
supporting efforts in preserving renal function after kid-
ney transplantation.
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